Summary
Maraviroc has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in HIV/AIDS would be drug repurposing rather than first-in-human development. This does not mean it is approved for HIV/AIDS. ClinicalTrials.gov lists 8 registered trials linking Maraviroc to HIV/AIDS: 6 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT01533272). The largest enrolment is 2500 participants (NCT00665561). Registration activity spans 2008 to 2016. The literature layer holds 14 publications for this pair: 5 Cochrane reviews, 3 meta-analyses, 1 systematic review and 5 clinical trial publications. Publication years run from 2015 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for HIV/AIDS ranks 249 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous elite control (natural viremic suppression without ART) in <1% of people living with HIV; untreated, median time to AIDS ~10 years; viral rebound within weeks of ART interruption in 99%+ of patients.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 73.0 (trials 23.0, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 0 active / not yet recruiting, 6 completed, 2 other |
| Linked publications | 14 (5 Cochrane reviews, 5 clinical trial publications, 3 meta-analyses, 1 systematic review) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT01533272 | Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) 2012 | completed | Phase 4 | 240 |
| NCT02302547 | Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy 2014 | completed | Phase 3 | 224 |
| NCT03708861 | Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients 2016 | withdrawn | Phase 3 | — |
| NCT00821535 | Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers 2009 | completed | Phase 1 | 12 |
| NCT00665561 | Prospective Observational Epidemiologic Study of Maraviroc's Safety 2008 | completed | Not applicable | 2,500 |
| NCT02961829 | Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure 2015 | completed | Not applicable | 30 |
| NCT01204905 | R5 Integrase Study in HIV-1 Naive Patients 2010 | completed | Not applicable | 7 |
| NCT00992654 | A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India | no_longer_available | Not applicable | — |
Published literature
- Cochrane review Effectiveness of interventions on cognitive decline risk for people living with HIV on antiretroviral therapy: a systematic reviewDesai R, Vera J, Barber T et al. · The lancet. Healthy longevity · 2026 · PMID 42140212
- Clinical trial publication Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical TrialLazzaro A, Vai D, Barco A et al. · Journal of acquired immune deficiency syndromes (1999) · 2024 · PMID 39250652
- Clinical trial publication Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP TrialCooper SE, Zhang S, Haines D et al. · AIDS and behavior · 2024 · PMID 39083151
- Clinical trial publication MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIVMcCabe L, Burns JE, Latifoltojar A et al. · AIDS (London, England) · 2024 · PMID 38819839
- Meta-analysis Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysisHelfer MS, Sprinz E · The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases · 2024 · PMID 39556960
- Clinical trial publication Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment RegimenStroffolini G, Lazzaro A, Barco A et al. · Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2023 · PMID 37906406
- Clinical trial publication Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver diseaseBradshaw D, Abramowicz I, Bremner S et al. · PloS one · 2023 · PMID 37450478
- Systematic review Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic ReviewToledo T, Castro T, Oliveira VG et al. · Clinical pharmacokinetics · 2023 · PMID 37561283
- Cochrane review Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysisPisaturo M, Onorato L, Russo A et al. · Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021 · PMID 33031949
- Meta-analysis Network meta-analysis of post-exposure prophylaxis randomized clinical trialsFernández I, de Lazzari E, Inciarte A et al. · HIV medicine · 2021 · PMID 33108035
- Meta-analysis HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysisMatume ND, Tebit DM, Bessong PO · AIDS research and therapy · 2020 · PMID 32033571
- Cochrane review Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapyPastori D, Mezzaroma I, Pignatelli P et al. · British journal of clinical pharmacology · 2019 · PMID 30575989
- Cochrane review Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysisAchhra AC, Mwasakifwa G, Amin J et al. · The lancet. HIV · 2016 · PMID 27470027
- Cochrane review Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsKryst J, Kawalec P, Pilc A · PloS one · 2015 · PMID 25933004
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Maraviroc approved for HIV/AIDS?
Maraviroc has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in HIV/AIDS would be drug repurposing rather than first-in-human development. This does not mean it is approved for HIV/AIDS. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Maraviroc in clinical trials for HIV/AIDS?
ClinicalTrials.gov lists 8 registered trials linking Maraviroc to HIV/AIDS: 6 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT01533272). The largest enrolment is 2500 participants (NCT00665561). Registration activity spans 2008 to 2016.
What does the evidence show for Maraviroc in HIV/AIDS?
Maraviroc has both completed registered trials and synthesis-level publications linked to HIV/AIDS. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.